Fundraising FoxBiotech Startups
11,077 companies tagged Biotech, with their investors and founders.
0 investors
MiHelper develops a medical device and runs clinical trials in the area of headache and migraine treatment, working with headache neurologists and clinical research specialists. It operates in the medtech and digital health space with a focus on neurology.
0 investors
0 investors
0 investors
0 investors
Microbion develops therapeutics targeting biofilm-associated infections, with a lead candidate (Pravibismane) in clinical development for diabetic foot ulcer, orthopedic implant, and respiratory infections. The company operates in the biotech industry.
0 investors
0 investors
Microvascular Tissues is a commercial-stage company that develops tissue-based medical solutions. The company was established as a spin-out from Tornier, Inc., now part of Stryker Corp.
0 investors
0 investors
Microvi is a biotechnology company that develops MicroNiche Engineering (MNE) biocatalyst systems for water and wastewater treatment, including nitrogen, nitrate, phosphorus, and hexavalent chromium removal, as well as industrial bioprocessing applications. It serves municipal water utilities and industrial customers across the United States and United Kingdom.
0 investors
0 investors
A biotech company focused on infectious diseases, drawing on clinical and pharmaceutical development expertise across areas such as fungal diseases, bacterial infections, and vaccines. The company is led by physicians and scientists with backgrounds in infectious disease research, clinical development, and commercialization.
0 investors
0 investors
0 investors
0 investors
0 investors
Minerva Biotechnologies develops cancer and stem cell therapeutics, including cancer immunotherapies aimed at solid tumors and preventing cancer metastasis. The company also works on patient-derived stem cells for regenerative medicine.
0 investors
MingSight Pharmaceuticals is a clinical-stage biopharmaceutical company developing MS-553, an orally administered selective protein kinase C (PKC) inhibitor. Its lead candidate targets diabetic macular edema and diabetic retinopathy in ophthalmology, as well as chronic lymphocytic leukemia and small lymphocytic lymphoma in oncology.
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors
0 investors